Eosinophilic Asthma Global Market Report 2025

The eosinophilic asthma market size has grown rapidly in recent years. It will grow from $2.69 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth during the historic period can be attributed to rising pollution levels, decreased immunity in the population, an increase in the prevalence of eosinophilic asthma, a higher occurrence of allergens and respiratory conditions, increased healthcare expenditure, and a surge in R&D activities.

The eosinophilic asthma market size is expected to see rapid growth in the next few years. It will grow to $6.01 billion in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth during the forecast period can be attributed to the increasing prevalence of respiratory diseases, rising awareness and diagnosis rates, expanding therapeutic indications for monoclonal antibodies, growing investment in healthcare infrastructure, and the advancement of personalized medicine approaches. Key trends in the forecast period include the development of targeted biologics, improved diagnostic tools, personalized treatment strategies, enhanced drug delivery systems, integration of digital health technologies, and the expansion of clinical trials for novel therapies.

The increasing prevalence of smoking habits is anticipated to drive the growth of the eosinophilic asthma market in the coming years. Smoking habits encompass the regular use of tobacco products, including the frequency, context, and duration of smoking, which are often influenced by psychological, social, and environmental factors. The rise in smoking habits can be attributed to factors such as heightened stress levels, targeted marketing by tobacco companies, lack of awareness regarding health risks, and the social acceptance of smoking in certain cultures. Eosinophilic asthma treatment plays a crucial role in reducing airway inflammation and enhancing lung function, which can support smoking cessation by mitigating the respiratory issues that contribute to continued smoking. For example, in December 2023, the National Health Service, a government department based in the UK, reported an estimated 408,700 hospital admissions related to smoking in 2022-23, an increase from 389,800 cases in 2021-22, reflecting a 4.8% rise. Consequently, the increasing smoking rates contribute to the expansion of the eosinophilic asthma market.

Leading companies in the eosinophilic asthma market are focusing on the development of innovative drugs designed to target specific immune pathways, reduce inflammation, and enhance patient outcomes through personalized treatment approaches. Monoclonal antibodies, a type of laboratory-engineered molecule, mimic the immune system’s ability to combat harmful pathogens such as viruses and bacteria. These molecules are produced by fusing a specific antibody-producing cell with a cancer cell, enabling large-scale production of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, announced that Fasenra received approval from China's National Medical Products Administration, a government agency in China, for the treatment of severe eosinophilic asthma. This condition is marked by high eosinophil levels, which contribute to inflammation and worsening asthma symptoms. Fasenra, a monoclonal antibody, works by targeting and depleting eosinophils through a distinctive mechanism. It enhances the immune response by binding to the IL-5 receptor on eosinophils, effectively lowering eosinophil levels in both blood and tissues. The treatment regimen consists of an initial loading phase, followed by maintenance doses, with patients receiving injections every four weeks for the first three doses and subsequently every eight weeks.

In February 2024, GSK plc, a UK-based biopharmaceutical company, acquired Aiolos Bio for $1 billion. This acquisition is aimed at strengthening GSK’s respiratory portfolio by focusing on severe asthma patients with low T2 inflammation. The deal allows GSK to expand its market reach and solidify its leadership in respiratory therapies while catering to a broader range of asthma patients. Aiolos Bio, a US-based biotechnology company, specializes in developing treatments for respiratory and inflammatory conditions, including eosinophilic asthma.

Major players in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in eosinophilic asthma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the eosinophilic asthma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Eosinophilic asthma is a type of asthma characterized by high levels of eosinophils, a specific type of white blood cell, which causes inflammation in the airways. This condition leads to severe symptoms such as breathing difficulties and frequent flare-ups, with limited response to traditional treatments such as inhaled steroids.

The primary disease types in eosinophilic asthma are severe eosinophilic asthma and mild to moderate eosinophilic asthma. Severe eosinophilic asthma is a more intense form, characterized by high eosinophil levels that contribute to airway inflammation. Treatment options include biologics, bronchodilators, corticosteroids, immunomodulators, and other therapies. These treatments are typically administered in hospitals, clinics, and other healthcare facilities.

The eosinophilic asthma market research report is one of a series of new reports that provides eosinophilic asthma market statistics, including the eosinophilic asthma industry's global market size, regional shares, competitors with an eosinophilic asthma market share, detailed eosinophilic asthma market segments, market trends and opportunities, and any further data you may need to thrive in the eosinophilic asthma industry. This eosinophilic asthma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The eosinophilic asthma market consists of sales of mepolizuma and benralizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.